Bayer, Astellas, Onyx Pharma (ONXX) Report Negative Outcome in Tarceva Phase 3 Safety, Efficacy Trial

Bayer HealthCare Pharmaceuticals, Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX), and Astellas Pharma Inc. report that a Phase 3 trial evaluating the efficacy and safety of the addition of Tarceva (erlotinib) tablets to Nexavar (sorafenib) tablets did not improve overall survival for patients with unresectable hepatocellular carcinoma (HCC) vs. Nexavar alone. The SEARCH (Sorafenib and Erlotinib, a rAndomized tRial protoCol for the treatment of patients with Hepatocellular carcinoma) trial compared Nexavar in combination with Tarceva to Nexavar alone. The safety and tolerability of the treatment combination were generally as expected based upon experience and use of the two products alone and there were no new or unexpected toxicities or changes to the respective product safety profiles observed. Data from this study will be presented at an upcoming scientific meeting. Nexavar is jointly developed by Bayer and Onyx. Tarceva is jointly marketed by Astellas and Genentech, a member of the Roche Group.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Sunshine Biopharma's (SBFM) Nora Pharma Receives Health Canada Approval for Niopeg, a Biosimilar of Neulasta(R)
• Silicon Labs (SLAB) Appoints Radhika Chennakeshavula as CIO
• Trump Media & Technology Group (DJT) send letter to Nasdaq over “naked” short selling